About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Cleveland | 16,969 Studies Near You | Clareo Health

Clinical Trials LocationsCleveland

Clinical Trials in Cleveland

Discover 16,969 clinical trials near Cleveland, Ohio. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 9041-9060 of 16,969 trials

TERMINATEDPhase 2< 1 mile

Pregabalin for the Treatment of Vulvodynia

NCT00853229

The purpose of this study is to determine whether pregabalin is effective in the treatment of vulvodynia.

VulvodyniaVulvar Vestibulitis

The Cleveland Clinic16 participantsStarted Feb 2009

Cleveland, Ohio, United States

TERMINATEDNA< 1 mile

LVRC IDE Crossover Study (Crossover From IDE Trial CLN0009)

NCT02059057

Crossover study for patients who were randomized to the Control Group in CLN0009 (NCT01608490).

Boston Scientific Corporation102 participantsStarted Dec 2013

Birmingham, Alabama, United States • Los Angeles, California, United States • Mountain View, California, United States +22 more locations

Find Trials by Condition in Cleveland

Breast Cancerin Cleveland Lung Cancerin Cleveland Prostate Cancerin Cleveland Colorectal Cancerin Cleveland Melanomain Cleveland Leukemiain Cleveland Lymphomain Cleveland Pancreatic Cancerin Cleveland Ovarian Cancerin Cleveland Brain Cancerin Cleveland

Data from ClinicalTrials.govTerms

COMPLETED< 1 mile

Biomarkers as Predictors of Suicidal Risk in Adolescents

NCT03014518

Suicide is one of the most devastating events in society at all levels. The primary goal of this study is to predict suicide in adolescents at risk. We will utilize blood biomarker measurement and clinical risk factor scales to develop a tool to identify adolescents at risk for suicide earlier, which will allow clinicians to prescribe timely treatment and prevent suicide.

Suicide, AttemptedSuicidal IdeationSuicidal Intention+1 more

The Cleveland Clinic80 participantsStarted Dec 2016

Cleveland, Ohio, United States

TERMINATEDPhase 3< 1 mile

QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

NCT03510897

This trial is designed to evaluate QPI-1002 versus placebo for the prevention of Major Adverse Kidney Events (MAKE) in subjects at high risk for acute kidney injury following cardiac surgery. Half of the participants will receive QPI-1002 while the other half will receive placebo.

Cardiac Surgery

Quark Pharmaceuticals1,043 participantsStarted Jun 2018

Birmingham, Alabama, United States • Los Angeles, California, United States • Los Angeles, California, United States +101 more locations

COMPLETEDPhase 211 miles

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

NCT03823391

This study will assess the safety, tolerability, and efficacy of ABBV-3373 in participants with moderately to severely active rheumatoid arthritis (RA) on background methotrexate (MTX) compared with adalimumab.

Rheumatoid Arthritis (RA)

AbbVie48 participantsStarted Mar 2019

Huntsville, Alabama, United States • Phoenix, Arizona, United States • Hemet, California, United States +27 more locations

COMPLETEDNA22 miles

Follow-up Study of Growth, Safety, and Efficacy of an Infant Formula for Healthy Term Infants

NCT04389606

The purpose of this two-month follow-up study is to continue to follow growth, safety, and other health outcomes of infants fed a new infant formula for term infants or comparator formula. A reference group of human milk-fed infants will also be followed. This study is designed in accordance with Good Clinical Practice guidelines.

HealthyTerm Infants

ByHeart311 participantsStarted May 2020

Birmingham, Alabama, United States • Tucson, Arizona, United States • Jonesboro, Arkansas, United States +24 more locations

TERMINATED30 miles

A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)

NCT04235621

This is a study with 2 parts. Part 1 comprises a visit to collect biological samples necessary for the molecular characterization of chronic kidney disease. Part 2 comprises an observational period of 5 visits over a period up to 8 weeks. During Part 2, baseline tests will be conducted, and urine will be collected approximately every 2 weeks for 8 weeks. Patients may participate in Part 1, Part 2, or both, and will be followed for up to 1 year consisting of data collection from the patient's medical records and home collection of urine samples every 4 months.

Glomerulosclerosis, Focal SegmentalMinimal Change DiseaseDiabetic Nephropathies

Goldfinch Bio, Inc.20 participantsStarted Dec 2019

Mesa, Arizona, United States • Glendale, California, United States • Victorville, California, United States +15 more locations

COMPLETEDPhase 451 miles

Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic® Endovascular System

NCT02159521

To evaluate the efficacy of ultrasound accelerated thrombolysis using the EkoSonic® Endovascular System with standard infusion of thrombolytic drug for post-thrombotic syndrome from chronic venous occlusion.

Deep Vein ThrombosisPost-thrombotic Syndrome

Boston Scientific Corporation81 participantsStarted Jul 2014

Los Angeles, California, United States • Aurora, Colorado, United States • Darien, Connecticut, United States +19 more locations

TERMINATEDPhase 351 miles

A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD)

NCT03610048

This study will assess the long-term safety and tolerability of ALKS 5461 as an adjunctive treatment for refractory MDD.

Refractory Major Depressive Disorder

Alkermes, Inc.175 participantsStarted Aug 2018

Tucson, Arizona, United States • Little Rock, Arkansas, United States • Los Alamitos, California, United States +31 more locations

COMPLETEDPhase 388 miles

A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

NCT03127956

The objective of this study is to assess the long-term safety of Olumacostat Glasaretil gel, 5.0% in patients with acne vulgaris

Dermira, Inc.748 participantsStarted Mar 2017

Guntersville, Alabama, United States • Glendale, Arizona, United States • Phoenix, Arizona, United States +91 more locations

COMPLETEDPhase 388 miles

A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris

NCT03028363

The objectives of this study are to assess the safety and efficacy of Olumacostat Glasaretil Gel compared to vehicle in patients with acne vulgaris

Dermira, Inc.759 participantsStarted Dec 2016

Phoenix, Arizona, United States • Anaheim, California, United States • Los Angeles, California, United States +46 more locations

COMPLETEDPhase 290 miles

Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer

NCT02593227

This Phase II trial evaluates the safety and immunogenicity of two doses of the Folate Receptor Alpha (FRα) peptide vaccine mixed with GM-CSF as a vaccine adjuvant, with or without a immune priming with cyclophosphamide, as a consolidation therapy after neoadjuvant or adjuvant treatment of patients with Stage IIb-III triple negative breast cancer (TNBC).

Marker Therapeutics, Inc.80 participantsStarted Apr 2016

Tampa, Florida, United States • Westwood, Kansas, United States • Baltimore, Maryland, United States +8 more locations

COMPLETEDPhase 2115 miles

A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

NCT02006472

This is a multicenter, multinational, randomized, parallel-group, double-blind, placebo-controlled, dose range finding study to compare the efficacy and safety of different doses of pridopidine versus placebo in the treatment of motor impairment in Huntington's Disease (HD).

Huntington's Disease

Prilenia408 participantsStarted Feb 2014

La Jolla, California, United States • Los Angeles, California, United States • Englewood, Colorado, United States +55 more locations

TERMINATEDPhase 4126 miles

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion

NCT02476994

This will be a descriptive study designed to evaluate the propensity for hospitalized pediatric patients treated adequately with Clinolipid or standard of care for up to 90 days to develop Essential Fatty Acid Deficiency (EFAD). Additionally, this study design will evaluate the safety and efficacy of using Clinolipid in a pediatric population.

Essential Fatty Acid Deficiency (EFAD)

Baxter Healthcare Corporation1 participantsStarted May 2015

Park Ridge, Illinois, United States • Indianapolis, Indiana, United States • Columbus, Ohio, United States +1 more locations

COMPLETEDPhase 3173 miles

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

NCT02346240

The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol compared to active comparator and placebo in adults with moderate to severe chronic plaque psoriasis.

PsoriasisPlaque Psoriasis

UCB Biopharma S.P.R.L.559 participantsStarted Feb 2015

Mobile, Alabama, United States • Little Rock, Arkansas, United States • Beverly Hills, California, United States +67 more locations

COMPLETEDNA308 miles

Study of Cryoablation for Metastatic Lung Tumors

NCT01957787

The purpose of this study is to evaluate the safety and efficacy of cryoablation therapy used to treat tumors in participants with pulmonary metastatic disease. This study is to enroll participants who will undergo cryoablation of at least 1 metastatic pulmonary tumor that is less than or equal to 3.5 centimeter (cm). Participants will be followed 24 months post their cryoablation procedure.

Neoplasm Metastasis

Boston Scientific Corporation131 participantsStarted Apr 2014

Los Angeles, California, United States • Newnan, Georgia, United States • Rochester, Minnesota, United States +7 more locations

WITHDRAWNPhase 2308 miles

Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia

NCT03532035

This is a randomized, controlled, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetic (PK), and adenovirus (AdV) antiviral activity of multiple ascending doses of IV brincidofovir (BCV). Approximately 30 eligible subjects will be sequentially enrolled into 1 of 3 planned cohorts. Within each cohort, subjects will be randomized in a 4:1 ratio to receive IV BCV dosed twice weekly (BIW) (on Days 1, 4, 8, and 11) or to receive investigator-assigned standard of care (SoC).

Jazz PharmaceuticalsStarted Dec 2018

Los Angeles, California, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +5 more locations

COMPLETEDPhase 2/3308 miles

Phase 2/3 Study of IGSC, 20% in PIDD

NCT01218438

The purpose of this study is to develop a 20% subcutaneous (SC) immunoglobulin preparation for the treatment of patients with primary immunodeficiency diseases (PIDD).

Primary Immunodeficiency Diseases (PID)

Baxalta now part of Shire86 participantsStarted Jan 2013

Irvine, California, United States • Centennial, Colorado, United States • North Palm Beach, Florida, United States +15 more locations

TERMINATEDPhase 2308 miles

Safety and Tolerability Study of AZD4831 in Patients With Heart Failure.

NCT03756285

A randomized, double-blind, placebo-controlled, parallel group, multicentre study in patients with Heart Failure with preserved Ejection Fraction (HFpEF). The study will be conducted at approximately 15 sites in 5 countries. Approximately 96 patients will be randomized to AZD4831 or placebo (treatment duration 90 days).

AstraZeneca41 participantsStarted Dec 2018

Chicago, Illinois, United States • Boston, Massachusetts, United States • Aarhus N, Denmark +10 more locations

RECRUITINGNA1114 miles

Breast Mesh Used in Two-staged Breast Reconstruction

NCT04967976

This is the first prospective randomized and controlled study on the efficacy and safety of TiLOOP® Bra mesh in patients with expander-implant breast reconstruction. The investigators hypothesize that incoporating TiLOOP Bra mesh with tissue expanders will reduce the rates of capsular contraction, improve the efficiency of expansion and provide better aesthetic result.

Breast CancerRadiationBreast Reconstruction+1 more

Tianjin Medical University Cancer Institute and Hospital300 participantsStarted Aug 2021

Houston, Texas, United States • Lanzhou, Gansu, China • Ch’ang-ch’un, Jilin, China +3 more locations

PreviousPage 453 of 849Next

Diabetes

in Cleveland

Heart Diseasein Cleveland